Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76


Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.

Hao J, Ci X, Xue H, Wu R, Dong X, Choi SYC, He H, Wang Y, Zhang F, Qu S, Zhang F, Haegert AM, Gout PW, Zoubeidi A, Collins C, Gleave ME, Lin D, Wang Y.

Eur Urol. 2018 Mar 12. pii: S0302-2838(18)30162-3. doi: 10.1016/j.eururo.2018.02.019. [Epub ahead of print]


Cellular plasticity and the neuroendocrine phenotype in prostate cancer.

Davies AH, Beltran H, Zoubeidi A.

Nat Rev Urol. 2018 Feb 20. doi: 10.1038/nrurol.2018.22. [Epub ahead of print] Review.


SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1.

Peacock JW, Takeuchi A, Hayashi N, Liu L, Tam KJ, Al Nakouzi N, Khazamipour N, Tombe T, Dejima T, Lee KC, Shiota M, Thaper D, Lee WC, Hui DH, Kuruma H, Ivanova L, Yenki P, Jiao IZ, Khosravi S, Mui AL, Fazli L, Zoubeidi A, Daugaard M, Gleave ME, Ong CJ.

EMBO Mol Med. 2018 Feb;10(2):219-238. doi: 10.15252/emmm.201707689.


Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.

Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV.

Eur Urol. 2017 Dec 16. pii: S0302-2838(17)31030-8. doi: 10.1016/j.eururo.2017.11.038. [Epub ahead of print]


Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia.

Melong N, Steele S, MacDonald M, Holly A, Collins CC, Zoubeidi A, Berman JN, Dellaire G.

Sci Rep. 2017 Oct 31;7(1):14698. doi: 10.1038/s41598-017-14413-w.


LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression.

Liang Y, Ahmed M, Guo H, Soares F, Hua JT, Gao S, Lu C, Poon C, Han W, Langstein J, Ekram MB, Li B, Davicioni E, Takhar M, Erho N, Karnes RJ, Chadwick D, van der Kwast T, Boutros PC, Arrowsmith CH, Feng FY, Joshua AM, Zoubeidi A, Cai C, He HH.

Cancer Res. 2017 Oct 15;77(20):5479-5490. doi: 10.1158/0008-5472.CAN-17-0496. Epub 2017 Sep 15.


Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition.

Ketola K, Munuganti RSN, Davies A, Nip KM, Bishop JL, Zoubeidi A.

Clin Cancer Res. 2017 Nov 15;23(22):6923-6933. doi: 10.1158/1078-0432.CCR-17-0901. Epub 2017 Sep 12.


Patient-derived xenografts: A platform for accelerating translational research in prostate cancer.

Davies AH, Wang Y, Zoubeidi A.

Mol Cell Endocrinol. 2018 Feb 15;462(Pt A):17-24. doi: 10.1016/j.mce.2017.03.013. Epub 2017 Mar 15.


Targeting Lyn regulates Snail family shuttling and inhibits metastasis.

Thaper D, Vahid S, Nip KM, Moskalev I, Shan X, Frees S, Roberts ME, Ketola K, Harder KW, Gregory-Evans C, Bishop JL, Zoubeidi A.

Oncogene. 2017 Jul 13;36(28):3964-3975. doi: 10.1038/onc.2017.5. Epub 2017 Mar 13.


MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2.

Das R, Gregory PA, Fernandes RC, Denis I, Wang Q, Townley SL, Zhao SG, Hanson AR, Pickering MA, Armstrong HK, Lokman NA, Ebrahimie E, Davicioni E, Jenkins RB, Karnes RJ, Ross AE, Den RB, Klein EA, Chi KN, Ramshaw HS, Williams ED, Zoubeidi A, Goodall GJ, Feng FY, Butler LM, Tilley WD, Selth LA.

Cancer Res. 2017 Feb 15;77(4):1021-1034. doi: 10.1158/0008-5472.CAN-16-2529. Epub 2016 Dec 23.


Clusterin as a therapeutic target.

Wilson MR, Zoubeidi A.

Expert Opin Ther Targets. 2017 Feb;21(2):201-213. doi: 10.1080/14728222.2017.1267142. Epub 2016 Dec 16. Review.


Chaperoning the Cancer: The Proteostatic Functions of the Heat Shock Proteins in Cancer.

Vahid S, Thaper D, Zoubeidi A.

Recent Pat Anticancer Drug Discov. 2017;12(1):35-47. doi: 10.2174/1574892811666161102125252. Review.


The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.

Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, Jama R, Nip KM, Angeles A, Johnson F, Wyatt AW, Fazli L, Gleave ME, Lin D, Rubin MA, Collins CC, Wang Y, Beltran H, Zoubeidi A.

Cancer Discov. 2017 Jan;7(1):54-71. doi: 10.1158/2159-8290.CD-15-1263. Epub 2016 Oct 26.


BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer.

Luk IS, Shrestha R, Xue H, Wang Y, Zhang F, Lin D, Haegert A, Wu R, Dong X, Collins CC, Zoubeidi A, Gleave ME, Gout PW, Wang Y.

Clin Cancer Res. 2017 Mar 15;23(6):1542-1551. doi: 10.1158/1078-0432.CCR-16-0718. Epub 2016 Sep 23.


Molecular chaperone Hsp27 regulates the Hippo tumor suppressor pathway in cancer.

Vahid S, Thaper D, Gibson KF, Bishop JL, Zoubeidi A.

Sci Rep. 2016 Aug 24;6:31842. doi: 10.1038/srep31842.


Corrigendum re: "Suppression of Heat Shock Protein 27 Using OGX-427 Induces Endoplasmic Reticulum Stress and Potentiates Heat Shock Protein 90 Inhibitors to Delay Castrate-resistant Prostate Cancer" [Eur Urol 2014;66:145-55].

Lamoureux F, Thomas C, Yin MJ, Fazli L, Zoubeidi A, Gleave ME.

Eur Urol. 2016 Jul;70(1):e27-e28. doi: 10.1016/j.eururo.2016.03.014. Epub 2016 Mar 31. No abstract available.


A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer.

Selth LA, Das R, Townley SL, Coutinho I, Hanson AR, Centenera MM, Stylianou N, Sweeney K, Soekmadji C, Jovanovic L, Nelson CC, Zoubeidi A, Butler LM, Goodall GJ, Hollier BG, Gregory PA, Tilley WD.

Oncogene. 2017 Jan 5;36(1):24-34. doi: 10.1038/onc.2016.185. Epub 2016 Jun 6.


Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer.

Toren P, Kim S, Johnson F, Zoubeidi A.

PLoS One. 2016 Apr 5;11(4):e0152861. doi: 10.1371/journal.pone.0152861. eCollection 2016.


The Androgen Receptor Bridges Stem Cell-Associated Signaling Nodes in Prostate Stem Cells.

Davies AH, Zoubeidi A.

Stem Cells Int. 2016;2016:4829602. doi: 10.1155/2016/4829602. Epub 2016 Jan 10. Review.


Erratum: Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts.

Trerotola M, Ganguly KK, Fazli L, Fedele C, Lu H, Dutta A, Liu Q, De Angelis T, Riddell LW, Riobo NA, Gleave ME, Zoubeidi A, Pestell RG, Altieri DC, Languino LR.

Oncotarget. 2015 Oct 20;6(32):34038. doi: 10.18632/oncotarget.6187. No abstract available.


Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer.

Li J, Karki A, Hodges KB, Ahmad N, Zoubeidi A, Strebhardt K, Ratliff TL, Konieczny SF, Liu X.

Mol Cell Biol. 2015 Dec;35(24):4185-98. doi: 10.1128/MCB.00825-15. Epub 2015 Oct 5.


The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer.

Akamatsu S, Wyatt AW, Lin D, Lysakowski S, Zhang F, Kim S, Tse C, Wang K, Mo F, Haegert A, Brahmbhatt S, Bell R, Adomat H, Kawai Y, Xue H, Dong X, Fazli L, Tsai H, Lotan TL, Kossai M, Mosquera JM, Rubin MA, Beltran H, Zoubeidi A, Wang Y, Gleave ME, Collins CC.

Cell Rep. 2015 Aug 11;12(6):922-36. doi: 10.1016/j.celrep.2015.07.012. Epub 2015 Jul 30.


A Novel Triazole Nucleoside Suppresses Prostate Cancer Cell Growth by Inhibiting Heat Shock Factor 1 and Androgen Receptor.

Xia Y, Wang M, Beraldi E, Cong M, Zoubeidi A, Gleave M, Peng L.

Anticancer Agents Med Chem. 2015;15(10):1333-40.


Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts.

Trerotola M, Ganguly KK, Fazli L, Fedele C, Lu H, Dutta A, Liu Q, De Angelis T, Riddell LW, Riobo NA, Gleave ME, Zoubeidi A, Pestell RG, Altieri DC, Languino LR.

Oncotarget. 2015 Jun 10;6(16):14318-28. Erratum in: Oncotarget. 2015 Oct 20;6(32):34038.


Regulation of tumor cell plasticity by the androgen receptor in prostate cancer.

Bishop JL, Davies A, Ketola K, Zoubeidi A.

Endocr Relat Cancer. 2015 Jun;22(3):R165-82. doi: 10.1530/ERC-15-0137. Epub 2015 May 1. Review.


Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.

Shiota M, Bishop JL, Takeuchi A, Nip KM, Cordonnier T, Beraldi E, Kuruma H, Gleave ME, Zoubeidi A.

Oncotarget. 2015 Apr 20;6(11):9086-98.


A low carbohydrate, high protein diet suppresses intratumoral androgen synthesis and slows castration-resistant prostate tumor growth in mice.

Fokidis HB, Yieng Chin M, Ho VW, Adomat HH, Soma KK, Fazli L, Nip KM, Cox M, Krystal G, Zoubeidi A, Tomlinson Guns ES.

J Steroid Biochem Mol Biol. 2015 Jun;150:35-45. doi: 10.1016/j.jsbmb.2015.03.006. Epub 2015 Mar 19.


Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy.

Lelj-Garolla B, Kumano M, Beraldi E, Nappi L, Rocchi P, Ionescu DN, Fazli L, Zoubeidi A, Gleave ME.

Mol Cancer Ther. 2015 May;14(5):1107-16. doi: 10.1158/1535-7163.MCT-14-0866. Epub 2015 Mar 4.


Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.

Yamamoto Y, Loriot Y, Beraldi E, Zhang F, Wyatt AW, Al Nakouzi N, Mo F, Zhou T, Kim Y, Monia BP, MacLeod AR, Fazli L, Wang Y, Collins CC, Zoubeidi A, Gleave M.

Clin Cancer Res. 2015 Apr 1;21(7):1675-87. doi: 10.1158/1078-0432.CCR-14-1108. Epub 2015 Jan 29.


Targeting heat shock proteins in metastatic castration-resistant prostate cancer.

Azad AA, Zoubeidi A, Gleave ME, Chi KN.

Nat Rev Urol. 2015 Jan;12(1):26-36. doi: 10.1038/nrurol.2014.320. Epub 2014 Dec 16. Review.


Clusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survival.

Zhang F, Kumano M, Beraldi E, Fazli L, Du C, Moore S, Sorensen P, Zoubeidi A, Gleave ME.

Nat Commun. 2014 Dec 12;5:5775. doi: 10.1038/ncomms6775.


Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer.

Munuganti RS, Hassona MD, Leblanc E, Frewin K, Singh K, Ma D, Ban F, Hsing M, Adomat H, Lallous N, Andre C, Jonadass JP, Zoubeidi A, Young RN, Guns ET, Rennie PS, Cherkasov A.

Chem Biol. 2014 Nov 20;21(11):1476-85. doi: 10.1016/j.chembiol.2014.09.012.


PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.

Bishop JL, Sio A, Angeles A, Roberts ME, Azad AA, Chi KN, Zoubeidi A.

Oncotarget. 2015 Jan 1;6(1):234-42.


Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer.

Toren PJ, Kim S, Pham S, Mangalji A, Adomat H, Guns ES, Zoubeidi A, Moore W, Gleave ME.

Mol Cancer Ther. 2015 Jan;14(1):59-69. doi: 10.1158/1535-7163.MCT-14-0521. Epub 2014 Oct 28.


Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro.

Pham S, Deb S, Ming DS, Adomat H, Hosseini-Beheshti E, Zoubeidi A, Gleave M, Guns ES.

J Steroid Biochem Mol Biol. 2014 Oct;144 Pt B:436-44. doi: 10.1016/j.jsbmb.2014.09.004. Epub 2014 Sep 6.


Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.

Toren P, Kim S, Cordonnier T, Crafter C, Davies BR, Fazli L, Gleave ME, Zoubeidi A.

Eur Urol. 2015 Jun;67(6):986-990. doi: 10.1016/j.eururo.2014.08.006. Epub 2014 Aug 20.


Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma.

Lamoureux F, Baud'huin M, Ory B, Guiho R, Zoubeidi A, Gleave M, Heymann D, Rédini F.

Oncotarget. 2014 Sep 15;5(17):7805-19.


Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer.

Zardan A, Nip KM, Thaper D, Toren P, Vahid S, Beraldi E, Fazli L, Lamoureux F, Gust KM, Cox ME, Bishop JL, Zoubeidi A.

Oncogenesis. 2014 Aug 18;3:e115. doi: 10.1038/oncsis.2014.30.


Hsp27 regulates EGF/β-catenin mediated epithelial to mesenchymal transition in prostate cancer.

Cordonnier T, Bishop JL, Shiota M, Nip KM, Thaper D, Vahid S, Heroux D, Gleave M, Zoubeidi A.

Int J Cancer. 2015 Mar 15;136(6):E496-507. doi: 10.1002/ijc.29122. Epub 2014 Dec 4.


Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities (review).

Toren P, Zoubeidi A.

Int J Oncol. 2014 Nov;45(5):1793-801. doi: 10.3892/ijo.2014.2601. Epub 2014 Aug 14. Review.


The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer.

Bishop JL, Thaper D, Zoubeidi A.

Cancers (Basel). 2014 Apr 9;6(2):829-59. doi: 10.3390/cancers6020829.


Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth.

Takeuchi A, Shiota M, Beraldi E, Thaper D, Takahara K, Ibuki N, Pollak M, Cox ME, Naito S, Gleave ME, Zoubeidi A.

Mol Cell Endocrinol. 2014 Mar 25;384(1-2):117-25. doi: 10.1016/j.mce.2014.01.012. Epub 2014 Feb 1.


Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.

Lamoureux F, Thomas C, Yin MJ, Fazli L, Zoubeidi A, Gleave ME.

Eur Urol. 2014 Jul;66(1):145-55. doi: 10.1016/j.eururo.2013.12.019. Epub 2013 Dec 29. Erratum in: Eur Urol. 2016 Jul;70(1):e27-e28.


Rational cotargeting of Pim-1 and Akt in prostate cancer.

Toren P, Zoubeidi A.

Expert Rev Anticancer Ther. 2013 Aug;13(8):937-9. doi: 10.1586/14737140.2013.816461.


Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.

Thomas C, Lamoureux F, Crafter C, Davies BR, Beraldi E, Fazli L, Kim S, Thaper D, Gleave ME, Zoubeidi A.

Mol Cancer Ther. 2013 Nov;12(11):2342-55. doi: 10.1158/1535-7163.MCT-13-0032. Epub 2013 Aug 21.


The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer.

Rocha J, Zouanat FZ, Zoubeidi A, Hamel L, Benidir T, Scarlata E, Brimo F, Aprikian A, Chevalier S.

Mol Cell Endocrinol. 2013 Dec 5;381(1-2):140-9. doi: 10.1016/j.mce.2013.07.017. Epub 2013 Jul 30.


Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability.

Matsumoto H, Yamamoto Y, Shiota M, Kuruma H, Beraldi E, Matsuyama H, Zoubeidi A, Gleave M.

Cancer Res. 2013 Aug 15;73(16):5206-17. doi: 10.1158/0008-5472.CAN-13-0359. Epub 2013 Jun 20.


Dual inhibition of autophagy and the AKT pathway in prostate cancer.

Lamoureux F, Zoubeidi A.

Autophagy. 2013 Jul;9(7):1119-20. doi: 10.4161/auto.24921. Epub 2013 May 6.


A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.

Kuruma H, Matsumoto H, Shiota M, Bishop J, Lamoureux F, Thomas C, Briere D, Los G, Gleave M, Fanjul A, Zoubeidi A.

Mol Cancer Ther. 2013 May;12(5):567-76. doi: 10.1158/1535-7163.MCT-12-0798. Epub 2013 Mar 14.


Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer.

Shiota M, Bishop JL, Nip KM, Zardan A, Takeuchi A, Cordonnier T, Beraldi E, Bazov J, Fazli L, Chi K, Gleave M, Zoubeidi A.

Cancer Res. 2013 May 15;73(10):3109-19. doi: 10.1158/0008-5472.CAN-12-3979. Epub 2013 Mar 14.

Supplemental Content

Loading ...
Support Center